UNSPSC 51333202: Imiquimod

This classification denotes a biological response modifier with the molecular formula C14H16N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P1QW714R7M, chemically known as 4-amino-1-isobutyl-1h-imidazo(4,5-c)quinoline but generally known as imiquimod, which bears US NIH Compound Identifier 57469. European Medicines Agency schedules Imiquimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12453MIG.

UNSPSC 51333202 Imiquimod, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The single recent opportunity posted under this code—Seminole County, Florida's IFB 60459723LAS—solicits Naloxone and Safe Drug Deactivation Systems, products unrelated to imiquimod, a topical antiviral medication used primarily in dermatological and immunological applications. The mismatch between the code's intended commodity and the actual procurement suggests either a tagging error in the county's e-procurement system or a broader miscategorization. State and local health departments and counties may purchase imiquimod through pharmaceutical supply contracts, but the recent-opportunities block does not surface relevant activity under this code.

The single Seminole County opportunity, posted June 30, 2026 with a response deadline of July 26, 2023, requires vendors to deliver 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually on a quarterly schedule to the Seminole County Community Health Building in Sanford, Florida. Bidders must submit electronically through the county's e-Procurement Portal, include all shipping and delivery costs, provide unit pricing for each line item, maintain workers' compensation and general liability insurance, and comply with E-Verify and drug-free workplace requirements. The contract is structured as a two-year initial term with a one-year renewal option and includes a three-month probationary termination window. The procurement does not specify set-aside designations for disadvantaged enterprises and is potentially FEMA-funded, introducing federal environmental compliance obligations. The code itself does not support meaningful guidance for business development professionals evaluating imiquimod procurement opportunities in state and local markets at this time.